Two recent phase II trials, INDIBLADE and SURE-02, challenge the long-standing paradigm of mandatory radical local therapy for muscle-invasive bladder cancer (MIBC). As increasingly potent systemic induction treatment strategies emerge, a key question arises: can induction therapy response guide omission of radical surgery and radiotherapy to enable preservation of an intact, functioning bladder in selected patients?
Access to this article via Institution of Civil Engineers Library is not available. van der Heijden, A.
G. et al.
European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines. Eur.
Urol. 87 , 582–600 (2025).
Mellema, J. J.
et al. Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial.
Nat. Med.
https://doi.org/10.1038/s41591-026-04271-3 (2026). Necchi, A.
et al. Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study.
Lancet Oncol. 27 , 442–451 (2026).
van Dijk, N. et al.
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat.
Med. 26 , 1839–1844 (2020).
Vulsteke, C.
Nature Reviews Clinical Oncology published a clinical update in Oncology on 22 Apr 2026.
The item focuses on Systemic induction therapy and the expanding frontier of bladder preservation in MIBC.
Review the original article for the full source wording and details.